Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gershenson

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapyLynn C Hartmann, Karen H Lu, Gerald P Linette, et al.
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancerJonathan A Ledermann, Christian Marth, Mark S Carey, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
Ovarian cancer, version 3.2012Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)Philipp Harter, David Gershenson, Catherine Lhomme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapyLynn C Hartmann, Karen H Lu, Gerald P Linette, et al.
Gynecologic Oncology|November 28, 2017
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 StudyNeil S Horowitz, G Larry Maxwell, Austin Miller, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancerJonathan A Ledermann, Christian Marth, Mark S Carey, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancerRachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
Ovarian cancer, version 3.2012Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
Pageof 3